Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis
- PMID: 9624475
- PMCID: PMC105603
- DOI: 10.1128/AAC.42.6.1355
Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis
Abstract
The emergence of clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin has prompted a search for new and novel therapeutic agents active against S. aureus. Lysostaphin, a peptidase produced by Staphylococcus simulans, specifically cleaves the glycine-glycine bonds unique to the interpeptide cross-bridge of the S. aureus cell wall. The effectiveness of various regimens of dosing with intravenous lysostaphin was compared to that of vancomycin in the rabbit model of aortic valve endocarditis caused by a clinical methicillin-resistant S. aureus isolate. All animals were treated for a total of 3 days. The most active regimen, lysostaphin given three times daily, produced sterile vegetations in 10 of 11 treated rabbits, with a mean reduction in vegetation bacterial counts of 8.5 log10 CFU/g compared to the counts in the untreated controls. In contrast, vancomycin given twice daily sterilized no vegetations and reduced vegetation bacterial counts by only 4.8 log10 CFU/g. Lysostaphin given once daily was less effective, reducing mean vegetation bacterial counts by only 3.6 log10 CFU/g, but the combination of lysostaphin once daily and vancomycin twice daily reduced the mean vegetation bacterial density by 7.5 log10 CFU/g, a result that was significantly better than that for either regimen alone (P < 0.05). Lysostaphin was well tolerated by the rabbits, with no evidence of immunological reactions following up to 9 weeks of intravenous administration. We conclude that lysostaphin given alone or in combination with vancomycin is more effective in the treatment of experimental methicillin-resistant S. aureus aortic valve endocarditis than vancomycin alone.
Figures
Similar articles
-
Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin.Antimicrob Agents Chemother. 1999 Jul;43(7):1754-5. doi: 10.1128/AAC.43.7.1754. Antimicrob Agents Chemother. 1999. PMID: 10390235 Free PMC article.
-
Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.Antimicrob Agents Chemother. 2005 Aug;49(8):3163-5. doi: 10.1128/AAC.49.8.3163-3165.2005. Antimicrob Agents Chemother. 2005. PMID: 16048918 Free PMC article.
-
Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother. 2001 Aug;45(8):2304-8. doi: 10.1128/AAC.45.8.2304-2308.2001. Antimicrob Agents Chemother. 2001. PMID: 11451689 Free PMC article.
-
Lysostaphin: an antistaphylococcal agent.Appl Microbiol Biotechnol. 2008 Sep;80(4):555-61. doi: 10.1007/s00253-008-1579-y. Epub 2008 Jul 8. Appl Microbiol Biotechnol. 2008. PMID: 18607587 Review.
-
Therapeutic applications of lysostaphin against Staphylococcus aureus.J Appl Microbiol. 2021 Sep;131(3):1072-1082. doi: 10.1111/jam.14985. Epub 2021 Jan 18. J Appl Microbiol. 2021. PMID: 33382154 Review.
Cited by
-
Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother. 2003 Sep;47(9):3002-4. doi: 10.1128/AAC.47.9.3002-3004.2003. Antimicrob Agents Chemother. 2003. PMID: 12937013 Free PMC article.
-
The intersection of fracture healing and infection: Orthopaedics research society workshop 2021.J Orthop Res. 2022 Mar;40(3):541-552. doi: 10.1002/jor.25261. Epub 2022 Jan 25. J Orthop Res. 2022. PMID: 35076097 Free PMC article. Review.
-
Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin.Antimicrob Agents Chemother. 1999 Jul;43(7):1747-53. doi: 10.1128/AAC.43.7.1747. Antimicrob Agents Chemother. 1999. PMID: 10390234 Free PMC article.
-
Antimicrobial resistance: the example of Staphylococcus aureus.J Clin Invest. 2003 May;111(9):1265-73. doi: 10.1172/JCI18535. J Clin Invest. 2003. PMID: 12727914 Free PMC article. Review. No abstract available.
-
Lysostaphin-coated titan-implants preventing localized osteitis by Staphylococcus aureus in a mouse model.PLoS One. 2014 Dec 23;9(12):e115940. doi: 10.1371/journal.pone.0115940. eCollection 2014. PLoS One. 2014. PMID: 25536060 Free PMC article.
References
-
- Bayer A S, Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis. 1985;151:157–165. - PubMed
-
- Boyce J M, Medeiros A A. Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C: American Society for Microbiology; 1997. Clinical isolates of methicillin-resistant Staphylococcus aureus from the United States with subpopulations of cells with reduced susceptibility to vancomycin, abstr. LB-15; p. 6.
-
- Bramley A J, Foster R. Effects of lysostaphin on Staphylococcus aureus infections of the mouse mammary gland. Res Vet Sci. 1990;49:120–121. - PubMed
-
- Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. Morbid Mortal Weekly Rep. 1997;46:813–815. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical